base metals investing Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
base metals investing Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease Conference
base metals investing Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
base metals investing Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
base metals investing Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
base metals investing Acumen Pharmaceuticals Highlights Enhanced Brain Delivery ) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference 2026
base metals investing Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery ) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference 2026
base metals investing Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery ) Development Candidates for the Treatment of Alzheimer's Disease
base metals investing Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
base metals investing Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
base metals investing Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
base metals investing Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease Conference
base metals investing Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease Conference
CoTec Holdings Corp. Notes HyProMag USA Pre-Feasibility Study Outlining Future Expansion Options to Quadruple Planned U.S. Rare Earth Magnet Capacity, Indicating an Incremental Post-Tax NPV of Up to US$2.1 billion
